Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis
Background: Bevacizumab biosimilars are slowly making their way into cancer treatment, but the data on their efficacy and safety in cancer patients are still poor. We systematically summarized the current evidence for the efficacy and safety of bevacizumab biosimilars in patients with advanced non-s...
Saved in:
Main Authors: | Xinyi Xu (Author), Shengzhao Zhang (Author), Ting Xu (Author), Mei Zhan (Author), Chen Chen (Author), Chenyu Zhang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The combination of MnO2@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer
by: Jisong Zhang, et al.
Published: (2022) -
Genomic Landscape of Metastatic Lymph Nodes and Primary Tumors in Non-Small-Cell Lung Cancer
by: Bing Chen, et al.
Published: (2022) -
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
by: Di Cao, et al.
Published: (2023) -
Racial disparities in metastatic colorectal cancer outcomes revealed by tumor microbiome and transcriptome analysis with bevacizumab treatment
by: Lei Feng, et al.
Published: (2024) -
Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab
by: Suemin Park, et al.
Published: (2024)